All News

RheumNow Podcast square

Pre-exposure Prophylaxis for COVID-19 (4.22.22)

Jack Cush, MD

Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.

Read Article
vaccine,mRNA,Covid,vial

COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients

Jack Cush, MD

Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).

Survey data from 7005 vaccinated and unvaccinated, adult RMD respondents from 102 countries was analyzed.

Read Article
COVID,vaccinate,injection,green

Evusheld as Protective Therapy in High Risk COVID-19 Patients

Jack Cush, MD

A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19. 

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
cancer, melanoma, metastatic, cell

Increased Cancer Risk with Autoimmune Disorders

Jack Cush, MD

The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.

Read Article
cost.healthcare.jpg

The Effect of Socioeconomic Status on Lupus Outcomes

Jack Cush, MD

Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.

Read Article
lupus,nephritis,GN

Tacrolimus Measures Up in Lupus Nephritis Trial

MedPage Today

In a phase III trial, oral tacrolimus (Prograf) proved non-inferior to intravenous cyclophosphamide for treating lupus nephritis, researchers said.

Read Article
SLE (n=2428) pts followed for 224,295 Pt-months- Osteonecrosis seen in 122 pts (6.5/1,000 PtYrs). Higher ON risk - African Americans (2x), Male (1.8x), smokers (1.5x). Higher Rates w/ high dose prednisone (not pulse or IM TCA) https://t.co/omU9Z1Z3kU https://t.co/wceGoCcUBV

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients Putman et al has reported vaccine survey results from the C19-GRA in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD). https://t.co/sqsOHGThzV https://t.co/zeZrlDeQ9Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Taiwan claims data shows among 2050 new SLE, 783 on HCQ. HCQ had no effect on future development of CKD over 14 yrs. Yet some rec HCQ in all lupus nephritis to reduce kidney flares, ESKD and death. https://t.co/JS0ST1W0LW https://t.co/ihQp3d5rcy

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/0uKAKJVxri https://t.co/KuvEA2pzrg

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/S9LsDaSZNx https://t.co/lFWZJTh367

Links:

Dr. John Cush RheumNow ( View Tweet)
Increased Cancer Risk with Autoimmune Disorders (AID) The incidence and mortality of cancer among AID was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID. https://t.co/T2WkOWp0cA https://t.co/iNJioAvrIe

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic lit review of 5694 CTD pts (SLE, RA, IIM, SSc) admitted to the ICU shows overall risk of mortality was 33%. ICU admits mainly for sepsis (43%), flares(40%). Mortality risk was 70% in IIM, 40% SSc, 35% SLE subgroup, 20% RA. https://t.co/ubVujkLCNy https://t.co/nnJdO36imK

Links:

Dr. John Cush RheumNow ( View Tweet)
The Effect of Socioeconomic Status on Lupus Outcomes Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues. https://t.co/J1BMlsakGN https://t.co/BNhCN89Pqv

Links:

Dr. John Cush RheumNow ( View Tweet)
Your Lupus Questions from RNL 2022 Rheumatologists questions for Dr. Jack Cush QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/845D5KfUzY https://t.co/RtKopcTfiY

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 119 SLE pts (30 w CKD) shows urinary galectin-3 binding protein as a biomarker, increased w/ active LN, significantly (p<0.001)correlating w/ SLEDAI, SLICC RAS, histologic activity; higher in proliferative vs membranous LN (p=0.04) https://t.co/s8mRnfxIj6 https://t.co/s1OoiRy6Xi

Links:

Dr. John Cush RheumNow ( View Tweet)
Infection in lupus is suggested by very high CRP, PMN-lymph ratio (NLR) Plt-lymph ratio(PLR). Study of 104 hospitalized SLE found all very high w/ infx & Combined cutoffs of CRP >20 mg/L, NLR >3.5, PLR >151 had 87 sensitivity & 81% specificity for infx https://t.co/5SjFsrBiZp https://t.co/0Ipussd9fF

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Montreal General Hosp SLE cohort study of 489 SLE pts - 35% have Raynauds phenomena; RP in SLE assoc. w/ Female (OR 2.43), White (OR 1.85), CNS disease (OR 1.98), RNP Abs (OR 3.0); negatively assoc w/ hemolytic anemia & cellular casts https://t.co/5t3GL4jqrm https://t.co/gVVqccvtca

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast available on Lupus worries. Download wherever you get your podcasts. https://t.co/gU1mmRXYUi https://t.co/54IDshqNYd

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×